Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Purpose:

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML


Criteria:

Inclusion Criteria: - Ph+ CML on dasatinib therapy - Loss of cytogenetic or molecular response while on dasatinib therapy - On stable dose of dasatinib for a minimum of 12 weeks and with < 14 day interruption of treatment Exclusion Criteria: - Blast crisis CML - Autoimmune disease - Uncontrolled or significant cardiovascular disease


NCT ID:

NCT00732186


Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.